These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 2880037)
1. Prophylactic role for antibodies to Escherichia coli J5. Gould FK; Freeman R Lancet; 1987 Jan; 1(8526):215. PubMed ID: 2880037 [No Abstract] [Full Text] [Related]
2. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. Greisman SE; Johnston CA J Infect Dis; 1988 Jan; 157(1):54-64. PubMed ID: 2447200 [TBL] [Abstract][Full Text] [Related]
3. Antigenic homology of endotoxin with a coliform mastitis vaccine strain, Escherichia coli O111:B4 (J5). Tyler JW; Spears H; Nelson R J Dairy Sci; 1992 Jul; 75(7):1821-5. PubMed ID: 1500577 [TBL] [Abstract][Full Text] [Related]
4. Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins. Appelmelk BJ; Maaskant JJ; Verweij-van Vught AM; van der Meer NM; Thijs BG; MacLaren DM J Gen Microbiol; 1993 Nov; 139(11):2641-7. PubMed ID: 7506295 [TBL] [Abstract][Full Text] [Related]
5. [Anti-endotoxin core glycolipid antibody: the preparation of immune serum of E. Coli J5]. Xu XN; Li ZJ; Li YP Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Jun; 16(6):358-60. PubMed ID: 15182450 [TBL] [Abstract][Full Text] [Related]
6. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067 [TBL] [Abstract][Full Text] [Related]
7. [Establishment of hybridoma lines and protective study of monoclonal antibodies against lipid A of endotoxins]. Fu W; Xiao G; Yu P Zhonghua Yi Xue Za Zhi; 1995 Mar; 75(3):159-60, 190-1. PubMed ID: 7780823 [TBL] [Abstract][Full Text] [Related]
8. [Effect of immunization with Escherichia coli J5 on the course of experimental pyelonephritis in rats]. Straube E; Naumann G; Broschewitz U Z Urol Nephrol; 1988 Apr; 81(4):247-55. PubMed ID: 3041706 [TBL] [Abstract][Full Text] [Related]
9. Role of magnesium in the enzyme-linked immunosorbent assay for lipopolysaccharides of rough Escherichia coli strain J5 and Neisseria gonorrhoeae. Ito JI; Wunderlich AC; Lyons J; Davis CE; Guiney DG; Braude AI J Infect Dis; 1980 Oct; 142(4):532-7. PubMed ID: 6777436 [TBL] [Abstract][Full Text] [Related]
11. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. Siber GR; Kania SA; Warren HS J Infect Dis; 1985 Nov; 152(5):954-64. PubMed ID: 2413146 [TBL] [Abstract][Full Text] [Related]
12. Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid. Lugowski C; Jachymek W; Niedziela T; Rowinski S FEMS Immunol Med Microbiol; 1996 Nov; 16(1):21-30. PubMed ID: 8954349 [TBL] [Abstract][Full Text] [Related]
13. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. Baumgartner JD; Heumann D; Calandra T; Glauser MP J Infect Dis; 1991 Apr; 163(4):769-72. PubMed ID: 2010630 [TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides. Aydintug MK; Inzana TJ; Letonja T; Davis WC; Corbeil LB J Infect Dis; 1989 Nov; 160(5):846-57. PubMed ID: 2681436 [TBL] [Abstract][Full Text] [Related]
15. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708 [TBL] [Abstract][Full Text] [Related]
17. Effect of changes in number of doses and anatomic location for administration of an Escherichia coli bacterin on serum IgG1 and IgG2 concentrations in dairy cows. Erskine RJ; Brockett AR; Beeching ND; Hull RW; Bartlett PC Am J Vet Res; 2010 Jan; 71(1):120-4. PubMed ID: 20043791 [TBL] [Abstract][Full Text] [Related]